Expanded kit range enhances AAV vector characterisation

Bio-Rad Laboratories, Inc has introduced Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8. These kits enable accurate quantification of capsid titre, genome titre, and the percentage of full capsids in both purified and unpurified samples, supporting reliable AAV vector characterisation.

Expanding on the existing kits for AAV5 and AAV9, the new additions increase coverage to approximately 70% of the AAV gene therapy market. AAV2, the most commonly used serotype in clinical trials, and AAV8, with its distinct tissue-targeting properties, allow for tailored gene therapy applications.

Powered by Bio-Rad’s Droplet Digital™ PCR technology, the Vericheck ddPCR kits deliver absolute quantification with minimal sample volume. Designed for use with crude lysate or purified AAV preparations, they provide robust, reproducible data to assess critical quality attributes (CQAs) in AAV vector production. The kits ensure consistent measurement across production workflows, aligning with regulatory guidelines to streamline gene therapy development.

“AAVs are highly effective gene therapy vectors due to their broad tropism and nonpathogenic nature,” said Steve Kulisch, Vice President of Product Management, Digital Biology Group, Bio-Rad Laboratories. “By expanding our Vericheck ddPCR Empty-Full Capsid Kit portfolio to include four key AAV serotypes, we offer researchers a cost-effective, precise, and accessible solution for AAV vector characterisation.”

More information online